Atara Biotherapeutics, Inc. ATRA

ATRA Company Overview

Atara Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing T-cell immunotherapies for cancer and autoimmune diseases. The company operates within the biotechnology and cell therapy industries, with a primary emphasis on allogeneic, or donor-derived, T-cell therapies designed to target diseases associated with Epstein-Barr virus (EBV) and other immune-mediated conditions. Atara has historically concentrated on off-the-shelf cell therapies intended to improve scalability and accessibility compared with autologous approaches. Its principal revenue sources have included collaboration agreements, licensing arrangements, and milestone payments rather than sustained commercial product sales, reflecting its development-stage status.

The company was founded in 2012 and is headquartered in Thousand Oaks, California. Over time, Atara evolved from a broad immunotherapy platform company into a more focused developer of EBV-specific T-cell therapies and related immunology programs. A major strategic element in the company’s development has been its partnership activity, particularly around tab-cel (tabelecleucel), an allogeneic T-cell therapy investigated for EBV-driven post-transplant lymphoproliferative disease (PTLD). Public disclosures in SEC filings and investor materials indicate that Atara has repositioned portions of its pipeline and operational structure multiple times in response to financing conditions, regulatory developments, and clinical-stage priorities.